| Autor: |
Kumrić, Marko, Božić, Joško, Berntsen, Julia, Urlić, Hrvoje, Plosnić Todorić Marija Rafaela, Glavaš, Duška, Mirić, Dino, Mustapić, Ivona, Borovac, Josip Anđelo |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Popis: |
Background: A body of data confirmed survival and hospitalization benefit regarding the use of SGLT2 inhibitors (SGLT2is) in patients with heart failure (HF) across the spectrum of ejection fractions. However, their potential effect on the prevention of sudden cardiac death (SCD) is not sufficiently explored. Purpose: This study was designed to determine crude rates and the relative risk of SCD in patients with HF with respect to treatment with SGLT2i (dapagliflozin or empagliflozin, each 10 mg once daily) or placebo. Methods: By thorough search of MEDLINE and EMBASE electronic databases and application of prespecified exclusion criteria, we identified 66 potential studies. A total of 5 randomized controlled trials (RCTs) examining the use of SGLT2is in HF, conducted in the period from 2019 to 2022, were included in the meta-analysis. This included pivotal trials such as DAPA-HF, DECLARE-TIMI 58, DEFINE- HF, EMPEROR-Preserved, and DELIVER. The main outcome measure was the risk of SCD events among HF patients, for which a risk ratio (RR) and respective 95% confidence intervals (95% CI) were reported. Meta-analysis was performed by utilizing the Mantel- Haenszel method with the fixed-effects model. The heterogeneity across included trials was assessed by using the I2 test. P-values |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
